Probiotic Properties of Lactobacilli that could be Used Against Periodontitis

Abstract

Bacterial competitiveness appears to be an efficient way to fight pathogenic oral flora. This competition may be facilitated by probiotics, particularly in periodontal diseases. The aim of this study was to investigate the probiotic properties of 61 clinical isolates of oral lactobacilli.The inhibitory activity of the tested strains against periodontopathogens was assessed with the agar overlay technique. The results obtained, as well as those resulting from previous work, led us to select the nine most promising strains on which we conducted further tests, such as evaluating their coaggregation capacities with various oral species and the production of proinflammatory cytokines by PBMC. We also evaluated the safety of the probiotics by assessing their sensitivity to antibiotics. Their possible involvement in halitosis was investigated by testing their ability to produce volatile sulfur compounds.The results of the agar overlay technique showed that all the lactobacilli strains had an antibacterial activity against Tannerella forsythia, Treponema denticola, and Aggregatibacter actinomycetemcomitans. Fifty-two strains slightly inhibited the growth of P. gingivalis and only two had no activity on F. nucleatum. The nine strains tested did not coaggregate with P. gingivalis, T. forsythia, T. denticola or A. actinomycetemcomitans. Three strains strongly coaggregated with F. nucleatum. Only three strains produced lower IL-6 than the activator at the maximum concentration tested in this study. However, none of the 9 strains produced a greater amount of IL-8 than that obtained with 1 μg/ml of LPS. These results show us that all the strains were sensitive to the antibiotics tested, except for one strain which showed resistance to penicillin. The production of CSV by the strains remained below the threshold of halitosis. Among the 61 strains tested, 9 proved to be of interest including one that was particularly promising.

Lactobacillus Attenuate the Progression of Pancreatic Cancer Promoted by Porphyromonas Gingivalis in K-rasG12D Transgenic Mice

“…Previous animal experiments indicate that oral administration of P. gingivalis can cause changes in the intestinal flora and increase the risk of various diseases by changing its metabolic profiles [28,29]. Related studies also show that Lactobacillus and Bifidobacterium may have the ability to inhibit P. gingivalis [30,31]. A review study pointed out that there is a correlation between pancreatic cancer and P. gingivalis, and chronic pancreatitis has lower intestinal Lactobacillus and Bifidobacterium [32].…”

Reliability of MALDI-TOF mass spectrometry to identify oral isolates of Streptococcus salivarius and Lactobacillus spp

“…According to little but increasing number of randomized double-blind clinical studies, beneficial bacteria may play a role in maintaining oral health through their interaction with the oral microbiome, thereby contributing to a healthy microbial equilibrium and preventing oral infectious conditions (Bustamante et al, 2019;Gruner et al, 2016;Nadelman et al, 2018). The persistence in the oral cavity of these beneficial bacteria is therefore essential and like other authors, we believe that an adequate strategy is to use microorganisms directly isolated from their natural oral habitat as oral probiotics (Samot et al, 2017;Samot et al, 2011;Strahinic et al, 2007;Wescombe et al, 2012). However, prior to any clinical use, the selection and evaluation of potential probiotic candidates requires a multi-step approach starting with precise strain identification (FAO/ WHO, 2002).…”

“…(5'-GATTCTGTCAAAGAAGCC-3') targeting the dextranase gene of Streptococcus salivarius (Igarashi et al, 2001). Sixty-one lactobacilli strains, isolated from human salivary samples and previously identified, were used in this study (Román-Méndez et al, 2009;Samot et al, 2017). Sequencing of the 16S-rDNA fragment was performed for all strains using the primers FD1 et RD1 according to Weisburg et al(Weisburg et al, 1991).…”

Potential Use of Biotherapeutic Bacteria to Target Colorectal Cancer-Associated Taxa

“…There is little doubt that targeting this organism in the GI tract and that the potential development of microbiota-targeted therapies against F. nucleatum are promising research avenues. As F. nucleatum was first identified as a pathogen associated with periodontal disease, numerous studies demonstrate the potential use of oral strains to inhibit many dental pathogens in vitro, including strains of F. nucleatum [88][89][90][91]. For example, bio-yogurt was shown to have antimicrobial activity against a range of periodontal pathogens, including the F. nucleatum strains tested.…”